-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $6

Benzinga·11/11/2026 14:31:05
Diffusion vocale
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $8 to $6.